Apoptosis

, Volume 18, Issue 1, pp 110–120

p53 acetylation enhances Taxol-induced apoptosis in human cancer cells

  • Jae Hyeong Kim
  • Eun-Kyung Yoon
  • Hye-Jin Chung
  • Seong-Yeol Park
  • Kyeong-Man Hong
  • Chang-Hun Lee
  • Yeon-Su Lee
  • Kyungho Choi
  • Young Yang
  • Kyungtae Kim
  • In-Hoo Kim
Original Paper

Abstract

Microtubule inhibitors (MTIs) such as Taxol have been used for treating various malignant tumors. Although MTIs have been known to induce cell death through mitotic arrest, other mechanisms can operate in MTI-induced cell death. Especially, the role of p53 in this process has been controversial for a long time. Here we investigated the function of p53 in Taxol-induced apoptosis using p53 wild type and p53 null cancer cell lines. p53 was upregulated upon Taxol treatment in p53 wild type cells and deletion of p53 diminished Taxol-induced apoptosis. p53 target proteins including MDM2, p21, BAX, and β-isoform of PUMA were also upregulated by Taxol in p53 wild type cells. Conversely, when the wild type p53 was re-introduced into two different p53 null cancer cell lines, Taxol-induced apoptosis was enhanced. Among post-translational modifications that affect p53 stability and function, p53 acetylation, rather than phosphorylation, increased significantly in Taxol-treated cells. When acetylation was enhanced by anti-Sirt1 siRNA or an HDAC inhibitor, Taxol-induced apoptosis was enhanced, which was not observed in p53 null cells. When an acetylation-defective mutant of p53 was re-introduced to p53 null cells, apoptosis was partially reduced compared to the re-introduction of the wild type p53. Thus, p53 plays a pro-apoptotic role in Taxol-induced apoptosis and acetylation of p53 contributes to this pro-apoptotic function in response to Taxol in several human cancer cell lines, suggesting that enhancing acetylation of p53 could have potential implication for increasing the sensitivity of cancer cells to Taxol.

Keywords

Taxol p53 Apoptosis Acetylation Sirt1 HDAC inhibitor 

Supplementary material

10495_2012_772_MOESM1_ESM.tif (29.3 mb)
Supplementary material 1 (TIFF 29986 kb)
10495_2012_772_MOESM2_ESM.tif (209.3 mb)
Supplementary material 2 (TIFF 214362 kb)
10495_2012_772_MOESM3_ESM.tif (29.3 mb)
Supplementary material 3 (TIFF 30046 kb)

References

  1. 1.
    Sackett DL, Fojo T (1999) Taxanes and other microtubule stabilizing agents. Cancer Chemother Biol Response Modif 18:59–80PubMedGoogle Scholar
  2. 2.
    Shu CH, Yang W, Shih YL, Kuo ML, Huang TS (1997) Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis 2:463–470PubMedCrossRefGoogle Scholar
  3. 3.
    Matson DR, Stukenberg PT (2011) Spindle poisons and cell fate: a tale of two pathways. Mol Interventions 11:141–150CrossRefGoogle Scholar
  4. 4.
    Kops GJPL, Weaver BAA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5:773–785PubMedCrossRefGoogle Scholar
  5. 5.
    Sudo T, Nitta M, Saya H, Ueno NT (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64:2502–2508PubMedCrossRefGoogle Scholar
  6. 6.
    Clarke PA, Allan LA (2010) Destruction’s our delight: controlling apoptosis during mitotic arrest. Cell Cycle 9:4035–4036PubMedCrossRefGoogle Scholar
  7. 7.
    Harley ME, Allan LA, Sanderson HS, Clarke PR (2010) Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J 29:2407–2420PubMedCrossRefGoogle Scholar
  8. 8.
    Wertz IE, Kusam S, Lam C et al (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471:110–114PubMedCrossRefGoogle Scholar
  9. 9.
    Blagosklonny MV, Fojo T (1999) Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83:151–156PubMedCrossRefGoogle Scholar
  10. 10.
    Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72–79PubMedCrossRefGoogle Scholar
  11. 11.
    Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1:506–526PubMedGoogle Scholar
  12. 12.
    Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T (1997) p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 94:9679–9683PubMedCrossRefGoogle Scholar
  13. 13.
    Delia D, Mizutani S, Lamorte G, Goi K, Iwata S, Pierotti MA (1996) p53 activity and chemotherapy. Nat Med 2:724–725PubMedCrossRefGoogle Scholar
  14. 14.
    Giannakakou P, Nakano M, Nicolaou KC et al (2002) Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99:10855–10860PubMedCrossRefGoogle Scholar
  15. 15.
    Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609–622PubMedCrossRefGoogle Scholar
  16. 16.
    Ferreon JC, Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE (2009) Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc Natl Acad Sci USA 106:6591–6596PubMedCrossRefGoogle Scholar
  17. 17.
    Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB (2009) Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem 284:20197–20205PubMedCrossRefGoogle Scholar
  18. 18.
    Yamaguchi H, Woods NT, Piluso LG et al (2009) p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284:11171–11183PubMedCrossRefGoogle Scholar
  19. 19.
    Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133:612–626PubMedCrossRefGoogle Scholar
  20. 20.
    Stewart ZA, Tang LJ, Pietenpol JA (2001) Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20:113–124PubMedCrossRefGoogle Scholar
  21. 21.
    Damia G, Filiberti L, Vikhanskaya F et al (2001) Cisplatinum and Taxol induce different patterns of p53 phosphorylation. Neoplasia 3:10–16PubMedCrossRefGoogle Scholar
  22. 22.
    Ford J, Jiang M, Milner J (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65:10457–10463PubMedCrossRefGoogle Scholar
  23. 23.
    Bunz F, Dutriaux A, Lengauer C et al (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedCrossRefGoogle Scholar
  24. 24.
    Vaziri H, Dessain SK, Ng Eaton E et al (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149–159PubMedCrossRefGoogle Scholar
  25. 25.
    Ito A, Kawaguchi Y, Lai CH et al (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21:6236–6245PubMedCrossRefGoogle Scholar
  26. 26.
    Liu T, Liu PY, Marshall GM (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69:1702–1705PubMedCrossRefGoogle Scholar
  27. 27.
    Saito A, Yamashita T, Mariko Y et al (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592–4597PubMedCrossRefGoogle Scholar
  28. 28.
    Beckers T, Burkhardt C, Wieland H et al (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121:1138–1148PubMedCrossRefGoogle Scholar
  29. 29.
    Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R (2010) Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 30:3557–3564PubMedGoogle Scholar
  30. 30.
    Shi X, Kachirskaia I, Yamaguchi H et al (2007) Modulation of p53 Function by SET8-Mediated Methylation at Lysine 382. Mol Cell 27:636–646PubMedCrossRefGoogle Scholar
  31. 31.
    Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595–606PubMedCrossRefGoogle Scholar
  32. 32.
    Lohrum MA, Woods DB, Ludwig RL, Balint E, Vousden KH (2001) C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21:8521–8532PubMedCrossRefGoogle Scholar
  33. 33.
    Loewer A, Batchelor E, Gaglia G, Lahav G (2010) Basal dynamics of p53 reveal transcriptionally attenuated pulses in cycling cells. Cell 142:89–100PubMedCrossRefGoogle Scholar
  34. 34.
    Lassen U, Molife LR, Sorensen M et al (2010) A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br J Cancer 103:12–17PubMedCrossRefGoogle Scholar
  35. 35.
    Zuco V, De Cesare M, Cincinelli R et al (2011) Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS ONE 6:e29085PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Jae Hyeong Kim
    • 1
    • 2
  • Eun-Kyung Yoon
    • 1
    • 3
  • Hye-Jin Chung
    • 1
  • Seong-Yeol Park
    • 1
  • Kyeong-Man Hong
    • 1
  • Chang-Hun Lee
    • 1
  • Yeon-Su Lee
    • 1
  • Kyungho Choi
    • 1
    • 4
  • Young Yang
    • 2
  • Kyungtae Kim
    • 1
  • In-Hoo Kim
    • 1
  1. 1.Research Institute National Cancer CenterIlsandon-gu, Goyang-siKorea
  2. 2.Department of Life ScienceResearch Center for Woman’s Disease, Sookmyung Woman’s UniversitySeoulKorea
  3. 3.Division of Life and Phamaceutical Sciences, The graduate SchoolEwha Womans UniversitySeodaemun-gu, SeoulKorea
  4. 4.Department of Biochemistry and Molecular BiologySeoul National University college of MedicineJongno-gu, SeoulKorea

Personalised recommendations